Published in Cancer Discov on September 11, 2013
External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens. Int J Radiat Oncol Biol Phys (2015) 2.03
Ligand-dependent enhancer activation regulated by topoisomerase-I activity. Cell (2015) 1.74
Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget (2016) 1.44
ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer. Cancer Cell (2017) 1.38
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Mol Cell (2015) 1.12
DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell (2015) 1.04
An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. Br J Radiol (2014) 1.04
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal (2014) 1.03
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res (2015) 0.97
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis (2016) 0.95
Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med (2015) 0.93
Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst (2015) 0.92
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. Int J Mol Sci (2016) 0.91
DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene (2014) 0.90
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. Clin Cancer Res (2016) 0.86
Advances in the research and development of natural health products as main stream cancer therapeutics. Evid Based Complement Alternat Med (2015) 0.84
The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition. Mol Cancer Ther (2015) 0.83
Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer. Cancer Discov (2013) 0.83
miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res (2015) 0.82
Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep (2017) 0.81
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Front Oncol (2016) 0.79
The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. Endocr Relat Cancer (2014) 0.79
Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells. Cancer Res (2015) 0.79
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) (2017) 0.77
Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol (2016) 0.76
Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer. Endocr Relat Cancer (2015) 0.76
miR-762 promotes porcine immature Sertoli cell growth via the ring finger protein 4 (RNF4) gene. Sci Rep (2016) 0.76
The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study. Biomed Res Int (2015) 0.76
Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene (2016) 0.76
Φ-score: A cell-to-cell phenotypic scoring method for sensitive and selective hit discovery in cell-based assays. Sci Rep (2015) 0.75
Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep (2016) 0.75
Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease. Prostate Cancer Prostatic Dis (2016) 0.75
ATM Inhibition Potentiates Death of Androgen Receptor-inactivated Prostate Cancer Cells with Telomere Dysfunction. J Biol Chem (2015) 0.75
Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer. Cancer Lett (2017) 0.75
Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52. Mol Oncol (2017) 0.75
Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends Endocrinol Metab (2016) 0.75
Prostate cancer: understanding why. Nat Rev Cancer (2013) 0.75
Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth. Cancer Res (2015) 0.75
ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin. Cell Cycle (2015) 0.75
EAF2 regulates DNA repair through Ku70/Ku80 in the prostate. Oncogene (2016) 0.75
Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget (2015) 0.75
NRIP/DCAF6 stabilizes the androgen receptor protein by displacing DDB2 from the CUL4A-DDB1 E3 ligase complex in prostate cancer. Oncotarget (2017) 0.75
Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin. Oncotarget (2016) 0.75
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. Prostate Cancer Prostatic Dis (2017) 0.75
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer (2017) 0.75
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem (2016) 0.75
Physiological functions of programmed DNA breaks in signal-induced transcription. Nat Rev Mol Cell Biol (2017) 0.75
DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy. Oncotarget (2017) 0.75
Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer. Mol Cell Oncol (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics (2011) 25.76
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev (1999) 9.50
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med (2011) 7.46
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A (2002) 5.98
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol (2004) 3.96
Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1998) 2.92
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell (2012) 2.59
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol (2008) 2.30
Mechanistic constraints on diversity in human V(D)J recombination. Mol Cell Biol (1996) 1.86
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
Unequal signal and coding joint formation in human V(D)J recombination. Mol Cell Biol (1993) 1.24
Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys (2001) 1.14
Systematic identification of functional residues in mammalian histone H2AX. Mol Cell Biol (2012) 1.00
Castration therapy results in decreased Ku70 levels in prostate cancer. Clin Cancer Res (2013) 1.00
Why does androgen deprivation enhance the results of radiation therapy? Urol Oncol (2008) 0.94
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature (2010) 11.24
Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev (2006) 11.04
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
RNA polymerase is poised for activation across the genome. Nat Genet (2007) 9.57
Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell (2010) 8.79
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell (2006) 7.33
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A (2008) 6.42
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell (2009) 5.51
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol (2010) 5.35
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
A biochemical approach to identifying microRNA targets. Proc Natl Acad Sci U S A (2007) 5.16
Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet (2010) 5.12
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
What is a gene, post-ENCODE? History and updated definition. Genome Res (2007) 4.96
Genome-wide localization of the nuclear transport machinery couples transcriptional status and nuclear organization. Cell (2004) 4.95
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell (2009) 4.81
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (2008) 4.51
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41
Positional stability of single double-strand breaks in mammalian cells. Nat Cell Biol (2007) 4.35
RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments. Genes Dev (2007) 4.16
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature (2007) 4.12
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol (2004) 3.96
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A (2005) 3.93
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91
CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature (2005) 3.90
BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer (2011) 3.85
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys (2008) 3.78
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell (2008) 3.68
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65
Pseudogene.org: a comprehensive database and comparison platform for pseudogene annotation. Nucleic Acids Res (2006) 3.62
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61